Urology
Volume 57, Issue 4, Supplement 1 , Pages 81-85 , April 2001

Prostate cancer prevention strategies using antiproliferative or differentiating agents

  • Janet Walczak

      Affiliations

    • Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (JW, HW, MC)
    • ,
  • Hadley Wood

      Affiliations

    • Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (JW, HW, MC)
    • ,
  • George Wilding

      Affiliations

    • University of Wisconsin, Madison, Wisconsin, USA (GW)
    • ,
  • Thomas Williams Jr

      Affiliations

    • Ilex Oncology, Inc., San Antonio, Texas, USA (TW)
    • ,
  • Charles W Bishop

      Affiliations

    • BCI Inc., Madison, Wisconsin, USA (CWB), USA
    • ,
  • Michael Carducci

      Affiliations

    • Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (JW, HW, MC)
    • Corresponding Author InformationReprint requests: Michael Carducci, MD, Johns Hopkins Oncology Center, 1M88 Bunting Blaustein, 1650 Orleans Street, Baltimore, MD 21231-1000

References 

  1. Heston WD, Kadmon D, Lazan DW, et al.  Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethulornithine. Prostate. 1982;3:383–389
  2. Ahmad N, Feyes DK, Nieminen AL, et al.  Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst. 1997;89:1881–1886
  3. Paschka AG, Butler R, Young CY. Induction of apoptosis in prostate cancer cell lines by the green tea component, (1)-epigallocatechin-3-gallate. Cancer Lett. 1998;130:1–7
  4. Gupta S, Ahmad N, Mohan RR, et al.  Prostate cancer chemoprevention by green tea (in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase). Cancer Res. 1999;59:2115–2120
  5. Loprinzi CL, Messing EM, O’Fallon JR, et al.  Toxicity evaluation of difluoromethylornithine (doses for chemoprevention trials). Cancer Epidemiol Biomarkers Prev. 1996;5:371–374
  6. Eiseman JL, Rogers FA, Guo Y, et al.  Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diazridinyl-4,9-diazadodecane, results in therapeutic eficacy and enhanced radiosensitivity of human prostate cancer. Cancer Res. 1998;58:4864–4870
  7. Palyi I, Kremmer T, Kalnay A, et al.  Effects of methylacetylenic putrescine, an ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines. Anticancer Drugs. 1999;10:103–111
  8. Cipolla B, Guille F, Quemener B, et al.  The diagnostic value of erythrocyte polyamines (EPA) in prostatic adenocarcinoma (PA) (apropos of 100 patients). Prog Urol. 1992;2:50–57
  9. Mohan RR, Challa A, Gupta S, et al.  Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res. 1999;5:143–147
  10. Hwang DR, Mathias CJ, Welch MJ, et al.  Imaging prostate derived tumors with PET and N-(3-(18F) fluoropropyl) putrescine. Int J Rad Appl Instrum [B]. 1990;17:525–532
  11. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer?. Anticancer Res. 1990;10:1307–1311
  12. Corder EH, Guess HA, Hulka BS, et al.  Vitamin D and prostate cancer (a prediagnostic study with stored sera). Cancer Epidemiol Biomarkers Prev. 1993;2:467–472
  13. Chan JM, Giovannucci E, Andersson SO, et al.  Dairy products, calcium, phosphorus, vitamin D, and risk of prostate cancer. Cancer Causes Control. 1998;9:559–566
  14. Giovannucci E. Dietary influences of 1,25 (OH)2 vitamin D in relation to prostate cancer (a hypothesis). Cancer Causes Control. 1998;9:567–582
  15. Skowronski RJ, Peehl DM, and Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952–1960, 1993.
  16. Miller GJ, Stapleton GE, Ferrar JA, et al.  The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha, 25-dihydroxyvitamin D3. Cancer Res. 1992;52:515–520
  17. Schwartz GG, Oeler TA, Uskokovic MR, et al.  Human prostate cancer cells (inhibition of proliferation by vitamin D analogues). Anticancer Res. 1994;14:1077–1081
  18. Schwartz GG, Hill CC, Oeler TA, et al.  1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology. 1995;46:365–369
  19. Lucia MS, Anzano MA, Slayter MV, et al.  Chemopreventive activity of taxmoifen, N-(4-hydroxyphenyl) retinamide, and the vitamin D analogue Ro24–5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res. 1995;55:5621–5627
  20. Getzenberg RH, Light BW, Lapco PE, et al.  Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 1997;50:999–1006
  21. Zhao XY, Ly LH, Peehl DM, et al.  1 alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology. 1997;138:3290–3298
  22. Hsieh T, Wu JM. Induction of apoptosis and altered nuclear/cytoplasmic distribution of the androgen receptor and prostate-specific antigen by 1alpha, 25-dihydroxyvitamin D3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun. 1977;23:539–544
  23. Yu WD, McElwain MC, Modzelewski RA, et al.  Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst. 1998;90:134–141
  24. Reese DH, Gordon B, Gratzner HG, et al.  Effect of retinoic acid on the growth and morphology of a prostatic adenocarcinoma cell line cloned for the retinoid inducibility of alkaline phosphatase. Cancer Res. 1983;43:5443–5450
  25. Peehl DM, Wong ST, Stamey TA. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate. 1993;23:69–78
  26. de Vos S, Dawson MI, Holden S, et al.  Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cell. Prostate. 1997;32:115–121
  27. Samid D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest. 1993;91:2288–2295
  28. Thibault A, Cooper MR, Figg WD, et al.  A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. 1994;54:1690–1694
  29. Carducci MA, Nelson JB, Chan-Tack KM, et al.  Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Can Res. 1996;2:379–387
  30. Pineau T, Hudgins WR, Liu L, et al.  Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol. 1996;52:659–667
  31. Tong KP, David-Beabes G, Meeker A, et al: Phenylbutyrate (PB) has plieotropic effects on gene transcription and inhibits telomerase activity in human prostate cancer. Anticancer Res 17: 3953a, 1997. Abstract 62.
  32. Carducci MA, Bowling MK, Eisenberger M, et al: Phenylbutarate (PB) for refractory solid tumors: Phase I clinical and pharmacologic evaluation of intravenous and oral PB. Anticancer Res 17: 3972a, 1997. Abstract 103.
  33. Earnest DL. Piroxicam and other cyclooxygenase inhibitors (potential for cancer chemoprevention). J Cell Biochem. 1992;161(suppl):156–166
  34. Marnett LJ. Generation of mutagens during arachidonic acid metabolism. Cancer Metast Rev. 1994;13:303–308
  35. Giardiello FM. NSAID-induced polyp regression in familial adenomatous polyposis patients. Gastroenterol Clin North Am. 1996;25:349–361
  36. Bedi A. Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 1995;55:1811–1816
  37. Kousos M. Aspirin and other NSAIDs inhibit the proliferation of colon adenocarcinoma cells (effects on cell cycle and apoptosis (abstract)). Gastroenterology. 1995;108:478a
  38. Kawano S. NSAIDs and the microcirculation of the stomach. Gastroenterol Clin North Am. 1996;25:299–315
  39. Brooks PM. Nonsteroidal antiinflammatory drugs-differences and similarities. N Engl J Med. 1991;324:1716–1733
  40. Tsujii M, Kawano S, Tsuji S, et al.  Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1988;93:705–716
  41. Attiga FA, Fernandez PM, Manyak MJ, et al.  Inhibition of human prostate tumor cells invasion through a reconstituted basement membrane by the cyclooxygenase-2-selective inhibitor NS398 (abstract). Proc Am Assoc Cancer Res. 1999;40:563a
  42. Lim JTE, Yamamoto H, Buttyan R, et al.  The effects of sulindac derivatives on human prostate cancer cells (abstract). Proc Am Assoc Cancer Res. 1998;39:587a

PII: S0090-4295(00)00947-X

Urology
Volume 57, Issue 4, Supplement 1 , Pages 81-85 , April 2001

Article Tools